Investigators performed a subgroup analysis of patients in the phase 3 FIDELIO-DKD and FIGARO-DKD clinical trials comparing finerenone with placebo in patients with CKD and type 2 diabetes.
In a study of patients with CKD and/or heart failure on RAASi therapy, the proportion of patients who received dose reductions or had therapy discontinued after new-onset hyperkalemia increased with hyperkalemia severity.
Investigators sought to distinguish the underlying cause of hyperkalemia after solid organ transplantation, whether from medications or organ dysfunction.
Individuals with sickle cell disease tend to have an elevated estimated glomerular filtration rate compared with the general population, investigators noted.
Findings from the observational study indicate that the benefits of continuing RAAS inhibitor use outweigh the risks in patients with nondialysis chronic kidney disease.
Investigators found the highest risks of short-term hospital and emergency department visits among patients with very low and very high serum potassium levels.